LSTA Lisata Therapeutics, Inc.
-
Lisata Therapeutics Reported Earnings
Thursday, August 6, 2026 · 12:00 AM ET
Lisata Therapeutics (LSTA) reported a loss of $0.32 per share on revenue of $0.00 million for the second quarter ended June 2026. . Revenue fell 100.00% compared to the same quarter a year ago.
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.
Earnings Whisper Grade
—
Power Rating—
Reported Earnings
($0.32)
Earnings Whisper®
—
Consensus Estimate
—
Earnings Surprise
Earnings Growth
Reported Revenue
—
Revenue Estimate
—
Revenue Surprise
Revenue Growth